FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 297:418-423 August 25, 1977 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Since deferoxamine B, when administered as a single daily intramuscular injection of 0.75 g, is unable to promote sufficient urinary iron excretion to achieve net negative iron balance in siderosis, we evaluated its administration as a constant infusion over 24 hours. We compared intravenous and subcutaneous routes in 24 siderotic patients who had excreted 420 to 630 mg (mean, 480 mg) of iron per month on intramuscular therapy. With the intravenous route urinary iron excretions increased to 570 to 3690 mg (mean, 1595 mg) per month. Constant subcutaneous delivery was 90 per cent as effective as intravenous administration on a dose-for-dose basis. Noteworthy net cumulative urinary iron excretions (urinary iron excretions minus transfused iron), often in excess of 1 g per month, have been maintained in all patients. Constant subcutaneous deferoxamine administration may prove to be an effective and practical means of eliminating large quantities of iron in siderosis.

This article has been cited by other articles:

• Sheiner, E., Levy, A., Yerushalmi, R., Katz, M. (2004). Beta-Thalassemia Minor During Pregnancy. Obstet Gynecol 103: 1273-1277 [Abstract] [Full Text]  
• Schwartz, K. A., Li, Z., Schwartz, D. E., Cooper, T. G., Braselton, W. E. (2002). Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J. Appl. Physiol. 93: 746-751 [Abstract] [Full Text]  
• Hoffbrand, A.V. (2001). Diagnosing myocardial iron overload. Eur Heart J 22: 2140-2141  
• Kushner, J. P., Porter, J. P., Olivieri, N. F. (2001). Secondary Iron Overload. ASH Education Book 2001: 47-61 [Abstract] [Full Text]  
• Franchini, M., Gandini, G., de Gironcoli, M., Vassanelli, A., Borgna-Pignatti, C., Aprili, G. (2000). Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 95: 2776-2779 [Abstract] [Full Text]  
• Choudhury, R., Epemolu, R. O., Rai, B. L., Hider, R. C., Singh, S. (1997). Metabolism and Pharmacokinetics of 1-(2'-Trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. Drug Metab. Dispos. 25: 332-339 [Abstract] [Full Text]  
• Olivieri, N. F., Brittenham, G. M. (1997). Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 89: 739-761 [Full Text]  
• Allen, N.H.P., Burns, A. (1995). The treatment of Alzheimer's disease. J Psychopharmacol 9: 43-56  
• Brittenham, G. M., Griffith, P. M., Nienhuis, A. W., McLaren, C. E., Young, N. S., Tucker, E. E., Allen, C. J., Farrell, D. E., Harris, J. W. (1994). Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major. NEJM 331: 567-573 [Abstract] [Full Text]  
• Olivieri, N. F., Nathan, D. G., MacMillan, J. H., Wayne, A. S., Liu, P. P., McGee, A., Martin, M., Koren, G., Cohen, A. R. (1994). Survival in Medically Treated Patients with Homozygous {beta}-Thalassemia. NEJM 331: 574-578 [Abstract] [Full Text]  
• Oliver, D. (1988). Syringe drivers in palliative care: a review. Palliat Med 2: 21-26 [Abstract]